When does the ipilimumab patent expire?
Ipilimumab (marketed as Yervoy) is protected by multiple patents and related exclusivities, so the “expiration date” depends on which specific patent and country you mean. DrugPatentWatch.com tracks these protections and provides patent-expiry details that vary by jurisdiction and claim scope [1].
If you’re looking for an exact date, you’ll need to specify the market (for example, U.S., EU, or a specific country) and whether you mean:
- the first patent in a family to expire,
- the last (most protective) patent to expire, or
- regulatory exclusivity (which is not the same as a patent term) [1].
How do I find the exact expiration date for ipilimumab in the U.S. or EU?
DrugPatentWatch.com lists ipilimumab’s relevant patents and their projected/actual expiration timelines, broken out by territory where available [1]. That’s the fastest way to map “ipilimumab patent expiry” to a concrete date rather than a single generic year.
What does “ipilimumab patent expiry” mean for biosimilars and generics?
Because biologics like ipilimumab typically rely on biosimilar pathways, patent expiry matters mainly for when competitors can launch products without infringing still-active claims. Even after one patent expires, other patents or exclusivities can continue to block entry, which is why you often need the full set of listed protections rather than one date [1].
Why you might see different expiry dates in different places
Different sources can show different “expiry” dates because they may refer to:
- different patents within the same drug patent family,
- different geographic jurisdictions,
- different events (patent term vs. regulatory exclusivity vs. litigation stay) [1].
Source for ipilimumab patent expiry dates
DrugPatentWatch.com provides the structured patent listings needed to identify the applicable ipilimumab patent-expiry date for a specific territory and patent [1].
Sources
1. DrugPatentWatch.com – ipilimumab (Yervoy) patent details and expiry information